metaEvidence - mapping review

meta|evidence oncology

Living systematic review and meta-analysis

multiple myeloma - 2nd line (L2) 1
myofibroblastic tumors
neurofibroma
neutropenia
new pathology
osteosarcoma
ovarian cancer (OC) 9

bispecific antibody
mirvetuximab soravtansine-gynx
immune chekpoint inhibitors
anti-CTLA-4
tremelimumab
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel
atezolizumab plus SoC
avelumab based treatment
avelumab alone
avelumab plus pegylated liposomal doxorubicin
avelumab plus SoC
durvalumab based treatment
nivolumab based treatment
pembrolizumab based treatment
pembrolizumab plus SoC
Immune checkpoint association
durvalumab plus tremelimumab
nivolumab plus ipilimumab
poly ADP-ribose polymerase (PARP) inhibitor
niraparib
olaparib
rucaparib
target therapy
multikinase inhibitor
nintedanib
VEGF(R) inhibitor
bevacizumab based treatment
bevacizumab

versus all
vs chemotherapy
vs non platinum-based chemotherapy
vs anthracyclines
vs doxorubicin
vs pegylated liposomal doxorubicin
vs Standard of Care (SoC)
vs placebo plus SoC
vs immune chekpoint inhibitors
vs anti-PD-(L)1
vs durvalumab based treatment
vs durvalumab alone
vs nivolumab based treatment
vs nivolumab alone
vs Immune checkpoint association
vs durvalumab plus tremelimumab
vs poly ADP-ribose polymerase (PARP) inhibitor
vs olaparib
vs rucaparib
vs VEGF(R) inhibitor
vs bevacizumab based treatment
vs bevacizumab plus carboplatin and paclitaxel

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded

graph table EGM comparisons

click on circles to display study description...

LUME-Ovar 1 (AGO-OVAR 12), 2016 NCT01015118

nintedanib (n=911) vs. Standard of Care (SoC) (n=455)

randomized controlled trial

Studied treatment

nintedanib

Control treatment

placebo

six cycles of carboplatin (AUC 5 mg/mL per min or 6 mg/mL per min) and paclitaxel (175 mg/m(2))

Patients

ovarian cancer (OC)

Method

double-blind

Remark

powered by vis.js Network